Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Enovix Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Enovix Corporation trades at $4.56 (market cap $1.06B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 27.9× Enovix Corporation's market cap. Which is the better fit depends on your goals.
| ALNY | ENVX | |
|---|---|---|
Market Cap | $29.60B | $1.06B |
Sector | Health | Technology |
52-Week High | $491.22 | $13.19 |
52-Week Low | $205.48 | $3.68 |
Enterprise Value | $27.56B | $1.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
ENVX trades at $4.73, up 1.94% with a bullish technical signal despite negative profitability metrics. The company shows consistent earnings beats but operates at significant losses with a -499.64% net income margin. Recent positive developments include the appointment of a former Apple executive as COO and upcoming Q2 2026 earnings on August 12, 2026.
Analyst consensus remains strongly bullish with a $12.38 price target (162% upside), though execution risks are high given cash burn and negative margins. The stock offers speculative growth potential in advanced battery technology but requires careful risk management due to ongoing operational losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
